Abstract
Radioembolization (RE) has been established as an effective treatment for both primary and secondary liver cancers. However, work continues in the area of dose optimization, specifically in understanding dose to both tumor and normal tissue, which have been shown to be important determinants of oncologic outcomes and complications, respectively. Data comparing the two commercially available RE products in terms of dose distribution is lacking. The purpose of this study was to determine the difference in dose distribution of RE patients undergoing treatment with resin as compared to glass microspheres.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
